Form 4: Integrated BioPharma Inc. Director Exercises Stock Options, Acquires Shares

Christina Kay, Co-Chief Executive Officer and Director of Integrated BioPharma Inc., reports the acquisition of 144,445 shares of common stock through the exercise of stock options.

Summary

• On May 21, 2025, Christina Kay, Co-Chief Executive Officer and Director of Integrated BioPharma Inc. (INBP), acquired 144,445 shares of common stock by exercising stock options at a price of $0.09 per share.
• Following this transaction, Kay directly owns 1,473,467 shares of Integrated BioPharma Inc.
• The stock options exercised were granted on June 2, 2015, with a portion becoming exercisable immediately and the remainder vesting in subsequent years.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard transaction (exercise of stock options) by a company insider. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The exercise of stock options by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders, like directors and officers, trade in their company's stock. It provides transparency to the market regarding insider activity.

Stakeholder Impact

• The transaction could have a minor impact on shareholders by slightly diluting the existing shares, but it also signals confidence from a company insider.

Key Dates

Keywords

stock options, Form 4, INBP, Integrated BioPharma Inc., beneficial ownership, Christina Kay, executive compensation, securities, shares